CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Atomoxetine hydrochloride

Last Updated: January 25, 2005
Result type: Reports
Project Number: S0031
Product Line: Reimbursement Review

Generic Name: Atomoxetine hydrochloride

Brand Name: Strattera

Manufacturer: Eli Lilly Canada Inc.

Indications: Attention deficit hyperactivity disorder

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: September 28, 2005

Recommendation Type: Do not list